Published in final edited form as:

Clin Cancer Res. 2010 October 1; 16(19): 4843–4852. doi:10.1158/1078-0432.CCR-10-1206.

Hypoxia in Models of Lung Cancer: Implications for Targeted Therapeutics

Edward E. Graves^{1,*}, Marta Vilalta¹, Ivana K. Cecic¹, Janine T. Erler¹, Phuoc T. Tran¹, Dean Felsher², Leanne Sayles³, Alejandro Sweet-Cordero³, Quynh –Thu Le¹, and Amato J. Giaccia¹

¹Department of Radiation Oncology, Molecular Imaging Program at Stanford Stanford University Stanford, CA 94305 USA

²Department of Medicine, Molecular Imaging Program at Stanford Stanford University Stanford, CA 94305 USA

³Department of Pediatrics Molecular Imaging Program at Stanford Stanford University Stanford, CA 94305 USA

Abstract

Purpose—In order to efficiently translate experimental methods from bench to bedside, it is imperative that laboratory models of cancer mimic human disease as closely as possible. In this study we sought to compare patterns of hypoxia in several standard and emerging mouse models of lung cancer in order to establish the appropriateness of each for evaluating the role of oxygen in lung cancer progression and therapeutic response.

Experimental Design—Subcutaneous and orthotopic human A549 lung carcinomas growing in nude mice as well as spontaneous K-ras or Myc-induced lung tumors grown *in situ* or subcutaneously were studied using fluorodeoxyglucose (FDG) and fluoroazomycin arabinoside (FAZA) positron emission tomography (PET), and post-mortem by immunohistochemical observation of the hypoxia marker pimonidazole. The response of these models to the hypoxia-activated cytotoxin PR-104 was also quantified by formation of γ H2AX foci *in vitro* and *in vivo*. Finally, our findings were compared with oxygen electrode measurements of human lung cancers.

Results—Minimal FAZA and pimonidazole accumulation was seen in tumors growing within the lungs, while subcutaneous tumors showed substantial trapping of both hypoxia probes. These observations correlated with the response of these tumors to PR-104, and with the reduced incidence of hypoxia in human lung cancers relative to other solid tumor types.

Conclusions—These findings suggest that *in situ* models of lung cancer in mice may be more reflective of the human disease, and encourage judicious selection of preclinical tumor models for the study of hypoxia imaging and anti-hypoxic cell therapies.

Keywords

Hypoxia; PET; Lung cancer; Tumor models; Molecular imaging

* Address correspondence to: Edward Graves, Ph.D. Department of Radiation Oncology Stanford University 875 Blake Wilbur Dr., Room G-202 Stanford, CA 94305-5847 phone: (650) 723-5591 fax: (650) 498-4015 egraves@stanford.edu.

Introduction

The role of oxygen in the response of tumors to treatment has been noted since the experiments of Thomlinson (1) and Gray (2). Hypoxia is a common phenomenon in human tumors, with most tumors possessing lower oxygenation than their corresponding tissue of origin (3). An aggressive phenotype has been associated with hypoxic tumors, encompassing both the well-studied resistance of poorly oxygenated cancers to radiotherapy and chemotherapy as well as a propensity for hypoxic tumors to exhibit increased potential for invasion, growth, and metastasis (4-11). Given the enormous relevance of hypoxia and the hypoxic tumor phenotype to the clinical management of cancer, much attention has been given to the development of treatments that target hypoxic tumor cells. With the emergence of noninvasive methods for imaging hypoxia, the use of oxygen status as a factor in tumor staging, treatment selection, and radiotherapy planning has been advanced (3,12). In recent years several hypoxia-selective chemotherapeutics that specifically target and kill hypoxic cells have been investigated, including tirapazamine (13) and PR-104 (14). These agents offer the possibility of specifically targeting and overcoming hypoxia and the therapeutic resistance associated with which it is associated.

In order to establish and optimize hypoxia-targeted therapies it is necessary to study the application of these treatments in preclinical models of cancer. The most common experimental tumor model is one in which human tumor cells are grown subcutaneously in an immune-compromised mouse. This is a convenient model in that tumor growth can be observed visually, and the tumor is accessible for tissue sampling or treatment. More sophisticated orthotopic experimental tumor models in which neoplastic cells are implanted and grown within the organ from which they were derived have also existed for many years (15). These models have been demonstrated to exhibit metastatic behavior and therapeutic responses that more closely follow those encountered with the corresponding human cancers in the clinic (16-21). Vascular growth patterns within both primary orthotopic tumors and their metastases have been noted to differ significantly from those of primary and metastatic tumors of the same genotype grown subcutaneously (22). While tumor-associated vasculature is strongly influenced by the tumor itself, this observed difference between orthotopic and subcutaneous tumors suggests that orthotopically-grown tumors may be more clinically-relevant models of cancer in which to study the biology of this disease and evaluate novel therapeutic strategies. At present, humane strategies for orthotopic implantation and growth of tumors in mice exist for a number of cancer types, including brain, colon, head and neck, lung, ovarian, pancreas, and prostate. When grown in immune-compromised mice, these cancer modeling techniques permit the growth of human tumors within a laboratory animal. However, the xenograft nature of these models may interfere with tumor-stroma interactions and distinguish these models from the corresponding human disease. Therefore cancer biologists have used transgenic mouse technology to generate rodent strains that spontaneously develop tumors in order to more effectively recapitulate the natural history of tumorigenesis and tumor progression. These include the transgenic adenocarcinoma mouse prostate (TRAMP) model (23), and recently several tissue-specific oncogene-induced spontaneous cancers (24,25).

While it is generally accepted that orthotopic and spontaneous models of cancer provide experimental systems that are more relevant to human disease, subcutaneous tumor models remain the workhorse of cancer biology investigations. We therefore sought to investigate potential discrepancies in the tumor microenvironment between a number of preclinical models of lung cancer, in order to assess how model selection may affect the results of studies of tumor biology and therapeutic response. We employed both established and emerging methods of assessing hypoxia in this study, and compared the preclinical findings with measurements acquired from human lung tumors. Our findings encourage both judicious selection of models

for preclinical studies of lung cancer, as well as careful consideration and further study of the role of hypoxia in lung tumor progression and therapeutic response in the clinic.

Materials and Methods

Animal models

All animal experiments were performed according to a protocol approved by the Institutional Animal Care and Use Committee. Human A549 lung carcinoma cells bearing an activating K-ras mutation (26) were stably transfected with firefly luciferase and grown either subcutaneously or orthotopically in male nu/nu nude mice. To produce subcutaneous tumors, 10^6 tumor cells were injected beneath the skin on each shoulder of a mouse. In order to implant tumor cells in an orthotopic location, the mice were anesthetized and an incision was made on the abdomen just below the ribcage. Tumor cells were then injected into the base of the lung via a needle passed through the diaphragm. The injection site was then sealed with matrigel and the incision sutured, after which the mice were allowed to recover under supplemental analgesia. Tumor growth was monitored by weekly bioluminescence imaging studies acquired using an IVIS 200 imaging system (Caliper Biosciences, Alameda, CA).

Expression of the K-ras oncogene in cells of the lung of male nu/nu nude mice was induced using a nasally-delivered adeno-Cre construct delivered nasally to the lungs of transgenic mice bearing a Lox-Stop-Lox-K-ras gene as described previously (24), resulting in focal K-ras-positive lung lesions within 4-6 weeks of infection. Lung-specific expression of a tetracycline-inducible Myc oncogene vector and subsequent tumor induction was achieved in nude mice as described by Tran *et al.* (27) For both of these models, tumor formation in the lung was monitored by weekly X-ray computed tomography scans using an eXplore Locus RS120 microCT scanner (GE Health Care, Milwaukee, WI). Tumors generated in a subset of K-ras- and Myc-induced mice were harvested and used to produce cell lines *in vitro*.

MicroPET Imaging

FAZA was synthesized with a TracerLab FX-FN automated nucleophilic synthesis system (GE Health Care) using [^{18}F]-fluoride produced on a PETtrace cyclotron (GE Health Care), following the procedure of Reischl *et al.* (28) implemented on an FX-FN automated radiotracer synthesis module (GE Health Care). FDG was produced in a dedicated synthesis unit. Beginning eight weeks after tumor implantation, animals underwent FDG and FAZA microPET examinations on subsequent days every two weeks. Each subject received an intravenous injection of ~200 mCi in 100 mL of radiotracer before undergoing microPET imaging on a Rodent R4 scanner (Concorde Microsystems, Knoxville, TN). Circulation times between radiotracer injection and imaging were one hour for FDG and three hours for FAZA. During imaging, coincidence events were collected for 10 minutes and reconstructed into 3D image data using an ordered subsets expectation maximization algorithm. Data was quantified in units of percent injected dose per gram (% ID/g) and displayed and analyzed using region-of-interest (ROI) methods within the RT_Image software package (29). ROIs were drawn manually over visible tumor areas and over the entire lung volume, and the mean and standard deviation of pixels within these regions were calculated. In addition, an ROI was drawn for each mouse over normal skeletal muscle to quantify background uptake. Image intensities were considered both in units of percent injected dose per gram and the ratio of target to the measured background tissue uptake (T:B).

Immunohistochemistry

After microPET imaging, the hypoxia marker pimonidazole (Chemicon International Inc., Temecula, CA) was administered intravenously to mice at a dose of 100 mg per kg body weight. One hour after injection, the mice were humanely euthanized and the subcutaneous tumor or

the lungs were excised, fixed with formalin, embedded in paraffin, and cut into 4 μ m sections. After mounting on slides, these sections were stained for pimonidazole adducts using an anti-pimonidazole antibody as described previously (30).

Hypoxia-Targeted Chemotherapy

To assess the efficacy of a hypoxia-directed therapy on models of lung cancer, tumor cells grown *in vitro* and *in vivo* were treated with the dinitrobenzamide mustard PR-104, a drug that has been previously shown to selectively kill cells under hypoxic conditions (14). Cells harvested from Myc-induced murine lung cancers and from the Kras-induced murine lung cancer model as well as the human lung cancer cell line A549 were grown *in vitro*. Cells were plated in two well culture slides and treated the following day with 100 μ M PR-104 (Proacta Inc, San Diego, CA) for four hours under different oxygen concentrations (0.5%, 2%, and 21%). After the treatment period cells were rinsed with PBS and grown for 3 hours in standard conditions, then rinsed with PBS and fixed with 4% formalin for 15 minutes.

Immunohistochemistry (IHC) was performed by incubating with an anti-phospho-histone γ H2AX (Ser139) mouse monoclonal antibody (Millipore, Billerica, MA) at a 1:700 dilution for two hours at room temperature, followed by incubation with a Texas red horse anti-mouse IgG antibody (Vector Laboratories, Burlingame, CA) at a 1:80 dilution for one hour. Cell nuclei were stained with 4',6-diamidino-2-phenylindole (DAPI) solution (Millipore).

In addition, mice with K-ras- and Myc-inducible lung tumors as well as mice bearing subcutaneous A549 tumors were treated with 1.8 mmole per kg body weight of PR-104 delivered intraperitoneally. Eighteen hours after a single PR-104 treatment, mice were euthanized through CO₂ inhalation. The lungs of mice with tumors *in situ* were excised and inflated before fixing with 10% formalin for 24 hours. Lungs were then washed with PBS and embedded in paraffin. Subcutaneous A549 tumors were excised and fixed with 10% formalin for 24 hours before rinsing in PBS and embedding in paraffin. Mice with subcutaneous A549 tumors sacrificed one hour after treatment with a 10 Gy dose of ionizing radiation were analyzed as a positive control for γ H2AX induction *in vivo*. Microtome sections were generated and mounted on silanized slides. IHC was performed after antigen retrieval with 10mM citric acid (pH=6) by incubating with the anti-phospho-histone γ H2AX (Ser139) at 1:700 for twelve hours at 4°C followed by Texas red horse anti-mouse IgG (Vector Laboratories, Burlingame, CA) at a 1:80 dilution for one hour at room temperature. As above, staining for DAPI was used to visualize cell nuclei.

To quantify formation of γ H2AX foci on microscopy data, RT_Image was used to delineate cell nuclei based on the DAPI image, and then to compute the sum of all pixel intensities in the γ H2AX image within the DAPI-positive areas. The average total γ H2AX signal per cell was then computed and normalized to a measure of the background intensity for each microscopy image, and compared between samples.

Human Tumor pO₂ Measurements

Patients with histologically-verified lung cancer were studied using an oxygen electrode. At the time of surgical resection, a computerized Eppendorf pO₂ histogram (Sigma, Hamburg, Germany) was used to measure oxygen tensions within the tumor and adjacent normal tissue as described previously (31). The 60-100 individual oxygen measurements collected from each patient were analyzed by computing the median pO₂ as well as the fraction of measurements less than 2.5 mm Hg (HF2.5) and less than 10 mm Hg (HF10).

Results

In Vivo Imaging

A total of 25 tumor-bearing mice were studied: 5 with subcutaneous A549 tumors, 9 with orthotopically-implanted A549 lung carcinomas, 5 with spontaneous Myc-induced lung lesions, and 6 with spontaneous K-ras-induced lung lesions. The subcutaneous A549 lesions grew to approximately 0.5 cc volumes within 6 weeks, while the orthotopically-implanted A549 mice were monitored with bioluminescence imaging up to 30 weeks post-implantation, at which time the mice exhibited tumor-related morbidity and were humanely euthanized. The K-ras and Myc-induced tumors were followed with weekly microCT imaging over a period of 10 weeks and 30 weeks, respectively, consistent with other studies employing these models (24,27). PET imaging examinations were performed using well-established, late stage tumors of diameter 5-7 mm at 6 weeks (subcutaneous A549), 8 weeks (orthotopic A549), 8 weeks (spontaneous K-ras), and 30 weeks (spontaneous Myc) post-initiation.

Representative results of microCT, FDG-microPET, FAZA-microPET, and pimonidazole immunohistochemistry studies performed for terminal lung cancer-bearing mice are shown in Figure 1A. A conspicuous subcutaneous mass is apparent for the subcutaneous A549 tumor-bearing mouse on the microCT scan, which traps both FDG and FAZA as seen on the microPET images. A widespread hyperintensity is noticeable within the lungs of the orthotopic A549 tumor-bearing mouse on the microCT image. While the heart exhibits intense FDG accumulation as seen in the microPET examination, significant uptake of FDG is also noted in both lobes of the lung. However, no detectable FAZA uptake above background is noted in the vicinity of the lungs, except for a small hyperintensity coincident with the heart. In mice with lung-specific activation of the K-ras and Myc oncogenes, one or more large neoplastic masses were evident on the microCT scan. These lesions display intense accumulation of FDG that can be differentiated from cardiac uptake, but as in the orthotopic A549 mice no elevated trapping of FAZA within the volume of the lungs is evident. Pimonidazole staining of these tumor specimens following animal sacrifice and tissue harvesting is in agreement with the FAZA findings, showing minimal labeling of the orthotopic and spontaneous tumors while binding strongly to the subcutaneous lesion. Quantitative analysis of the complete set of microPET data collected from this subject population is shown in Figures 1B and 1C.

Hypoxia-Targeted Chemotherapy

Figure 2A shows representative γ H2AX (red) and DAPI (blue) immunohistochemistry results from human A549 cells, two Myc-induced cell lines (B7347 and B7348), and two K-ras induced cell lines (LKR10 and LKR13) treated with PR-104 *in vitro* under several oxygen conditions. In general, DNA damage as indicated by γ H2AX staining increases with decreasing oxygenation in all three cell types. These observations are quantified in Figure 2B, in which the average normalized γ H2AX staining per cell is plotted for each cell type and oxygen level. All three lines exhibit statistically-significant increases in γ H2AX staining between 21% and 0.5% O₂ ($P < 0.05$). Having observed the sensitivity of each of these cell types to hypoxia-mediated PR-104-induced DNA damage, the response of these tumors to PR-104 treatment *in vivo* was then measured. Figure 3 shows representative immunohistochemical slides collected from these tumors and quantification of the data collected. The dramatic increase in γ H2AX staining in PR-104-treated A549 tumors is statistically significant when compared to samples from untreated A549 tumors ($P < 0.0001$) as well as to untreated and PR-104-treated spontaneous Myc- and K-ras-induced lung tumors ($P < 0.0001$). Neither of the spontaneous tumor models exhibited a significant increase in γ H2AX signal after treatment with PR-104, compared with untreated controls.

Human Tumor pO₂ Measurements

A total of 24 patients with primary non small cell lung cancer comprised the clinical patient sample. Figure 4A shows the distribution of median tumor pO₂ for the lung cancers. The median pO₂ for this group of lung cancers was 13.5 mm Hg, with a range of 0.7 – 45.6 mm Hg. A previous multi-institutional study suggested that the hypoxic fraction HF2.5 (percent of measurements below 2.5 mm Hg) was the most predictive factor for survival in head and neck cancer, with a threshold HF2.5 of 20% (32). Therefore, we also evaluated the HF2.5 for this lung tumor sample, as well as the fraction of patients with HF2.5 $\geq$ 20%. In addition, we calculated HF10 and HF10 $\geq$ 20% in order to estimate how many human lung cancers would accumulate the hypoxia probes pimonidazole and FAZA, using 10 mm Hg as an approximate threshold for binding of these agents (33, 34). These data are presented in Figures 4B and 4C. The median HF2.5 and HF10 for this patient sample were 0.6% and 17.5%, respectively. 38.1% of patients exhibited an HF2.5 greater than or equal to 20%, while 47.6% of patients displayed HF10 greater than or equal to 20%.

Discussion

While cell culture systems allow rigorous investigation of the molecular biology of cancer, they lack components such as vasculature and immune responses that complicate extrapolation of results to the *in vivo* situation. Murine tumor models allow evaluation of cancer biology within an intact, living organism. The simplest mouse models of neoplasm involve the introduction of human cancer cells beneath the skin of immune-compromised mice. This technique facilitates the development of subcutaneous tumors genetically identical to those found in humans. However, it is generally acknowledged that the vasculature and correspondingly perfusion and oxygen status of these lesions may differ from human disease because of the immediate tissue environment of the subcutaneous space (21). While potentially more relevant orthotopic and spontaneous models of cancer have been developed (16,18,19), subcutaneous tumor models remain the workhorse of preclinical cancer biology research.

The goal of this study was to investigate the significance of model type in preclinical studies of hypoxia in lung cancer. The incidence of hypoxia was assessed in subcutaneous and orthotopic xenograft models of human cancer as well as in spontaneous oncogenes-induced murine lung tumors. While all tumors studied exhibited elevated metabolism and glycolytic activity as observed with FDG PET imaging, only the subcutaneous tumors demonstrated significant hypoxia as seen in both FAZA PET and pimonidazole immunohistochemical assays. Neither the orthotopic xenografts nor the spontaneous murine tumors exhibited significant uptake of FAZA or pimonidazole, suggesting that at both the microscopic and macroscopic levels these lesions are relatively well-oxygenated. The orthotopically-implanted A549 tumors grew as diffuse microscopic clusters of cells that eventually overtook the entire lung, as seen in the microCT image in Figure 1. This may account for the lack of hypoxia in this model, because small lesions interspersed within normal lung parenchyma would not be expected to exhibit poor oxygenation. However, both the K-ras- and Myc-induced spontaneous tumors grew as focal masses to large sizes (1 cc), similar to human lung cancer, and neither displayed measurable hypoxia either by macroscopic imaging or microscopic immunohistochemistry assays. The microscopic cause of this discrepancy in oxygenation between the tumor models was not investigated, but is presumed to be due to differences in the vascular networks formed by these tumors. Interestingly, these measures of tumoral hypoxia correlated with response to PR-104 treatment for all tumor types studied. While each tumor cell type responded to PR-104 *in vitro* under hypoxic conditions (Figure 2), only the subcutaneously grown A549 tumor xenograft exhibited a response to PR-104 *in vivo* (Figure 3), consistent with the observation of extensive hypoxia in this model.

The implications of these observations for preclinical studies of tumor biology and therapeutics are significant. Clearly the findings of preclinical studies of the efficacy of hypoxia-directed therapies such as tirapazamine (35), PR-104 (14), and HIF-1 inhibitors (36) will be inextricably tied to the models in which these investigations were conducted. The observations presented here demonstrate that such therapies will be preferentially effective in subcutaneous tumor models that have poor oxygenation, and less effective in orthotopic and spontaneous disease models. The appropriateness of each model type for these therapeutic investigations is dictated on which model is most reflective of human lung cancer. The oxygenation of human lung cancers measured here using an Eppendorf electrode is larger than comparable measures of head and neck (HN) cancer acquired by our group, in terms of median pO₂ (lung: 13.5 mm Hg, HN: 11.4 mm Hg) and HF2.5 (lung: 0.6%, HN: 12.4%), although these differences are not statistically significant. This is consistent with other reports that the median oxygenation of lung tumors is generally greater than other solid tumor types (37) and is in the transition oxygen range between strong and weak cellular accumulation of 2-nitroimidazole hypoxia probes such as FAZA (33,34). It is also interesting to note that initial studies of orthotopic and subcutaneous models of head and neck cancer conducted by our group have demonstrated the incidence of hypoxia in both model types, an observation which supports the hypothesis that these cancers have lower oxygenation *in situ* than lung tumors. A recent preliminary study of hypofractionated radiotherapy for lung tumors reported excellent three year primary and locoregional control rates (97.6% and 87.2%, respectively) (38). While the biologically effective dose delivered in this regimen is very large and may explain the response rates, it is interesting to note that according to classical radiobiology one would expect hypoxic tumors to respond poorly to such a hypofractionated radiotherapy course.

In vivo imaging of tumoral hypoxia is a technique that has been developed over the last 20 years (39). A number of hypoxia specific PET radiotracers, including ¹⁸F-fluoromisonidazole (FMISO), FAZA, ⁶⁴Cu-ATSM, and EF5, have been applied towards this end and many are now undergoing clinical evaluation. The ability of FAZA to label regions of hypoxic tissue has been evaluated in several preclinical studies (40,41), with FAZA uptake correlating with immunohistochemical electrode measures of hypoxia. Investigations of hypoxia in human lung cancer using nuclear medicine techniques have demonstrated ⁶⁰Cu-ATSM tumor:muscle ratios of 1.2-4.8 (mean 2.3, (42)), ¹⁸FMISO tumor:normal ratios of 1.17-3.76 (mean 1.92, (43)), and ^{99m}Tc-HL91 tumor:normal ratios of 1.13-1.90 (mean 1.57, (44)). In our clinical lung tumor cohort, we observed 47.6% of patients with an HF10 ≥ 20%. Using 10 mm Hg as a threshold for hypoxia probe binding and 20% as the minimum hypoxic fraction of a tumor required to be visible on a hypoxia nuclear medicine scan, this suggests that roughly half of these patients would give a positive imaging signal. Although this is a coarse estimate, it corresponds well to the imaging studies cited above. Variations in lung cancer oxygenation are evident from imaging studies, however it is informative to note that on average oxygen levels of lung tumors are higher than those of other solid tumors. This suggests that the absence of hypoxia in the orthotopic and spontaneous tumor models observed here using FAZA PET may be reflective of the reduced incidence of hypoxia in this tumor type when growing *in situ*.

While current data supports the conclusion that macroscopic PET imaging can differentiate between grossly hypoxic and well oxygenated tumors, what remains unclear is the dynamic range of this imaging modality. The majority of studies of the utility of hypoxia PET in predicting response to therapy have retrospectively stratified the sample populations into “hypoxic” and “normoxic” groups on the basis of the mean or median uptake seen on a hypoxia PET scan (35,42), which in practice results in a threshold on the order of a T:B ratio of 2. The group at the University of Washington studying FMISO have alternately devised a strategy for computing the fractional hypoxic volume of a tumor, using an threshold tumor:blood ratio of 1.2 (45). It is interesting to note that while recent radiobiological research has stressed the significance of the full spectrum of tissue oxygenation states from fully anoxic to normoxic

(46), in particular the potential importance of intermediately hypoxic cells in dictating hypoxic tumor therapeutic resistance, efforts to apply hypoxia PET as a clinical prognostic variable have generally characterized tumors through a binary, “hypoxic” or “normoxic” strategy. Although some preliminary positive retrospective studies employing such methods have yielded promising results (47), it remains to be seen whether this simplified assessment of the tumor microenvironment will prove effective in large scale clinical trials. Continued development of PET radiotracers with improved sensitivity and specificity for hypoxic tissue will undoubtedly increase enthusiasm for widespread adoption of hypoxia imaging as a staging examination.

Statement of Translational Relevance

The focus of this research is to establish the relevance of preclinical mouse models of lung cancer to the corresponding human disease. It is observed through our experiments that the most common mouse tumor model, the subcutaneous xenograft, may significantly overestimate the degree of hypoxia in these tumors. This calls into question the appropriateness of conclusions from tumor biology and therapy studies employing this model when translated into clinical practice. The findings of this research will influence model selection for future laboratory studies of lung tumor biology, improving the link between preclinical research and clinical practice.

Acknowledgments

We gratefully acknowledge the assistance of Drs. Frederick Chin, David Dick, and Tim Doyle for assistance with animal models, radiotracer production, and microPET imaging. This work was funded by grants from the Lerner family, the Charles Henry Leach II Foundation, NIH R01 CA131199, and NIH P01 CA067166.

Research Support: Charles Henry Leach II Foundation Lerner Family Foundation NIH R01 CA131199 NIH P01 CA067166

References

1. Thomlinson RH, Gray LH. The histological structure of some human lung cancers and the possible implications for radiotherapy. *British Journal of Cancer* 1955;9:539–49. [PubMed: 13304213]
2. Gray LH, Conger AD, Ebert M, Hornsey S, Scott OCA. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. *British Journal of Radiology* 1953;26:638–48. [PubMed: 13106296]
3. Höckel M, Vaupel P. Tumor Hypoxia: Definitions and Current Clinical, Biologic, and Molecular Aspects. *Journal of the National Cancer Institute* 2001;93:266–76. [PubMed: 11181773]
4. Young, SD.; Marshall, RS.; Hill, RP. Hypoxia induces DNA overreplication and enhances metastatic potential of murine tumor cells; *Proceedings of the National Academy of Sciences of the United States of America*; 1988. p. 9533-7.
5. Brizel DM, Scully SP, Harrelson JM, et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. *Cancer Research* 1996;56:941–3. [PubMed: 8640781]
6. Höckel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. *Cancer Research* 1996;56:4509–915. [PubMed: 8813149]
7. Brizel DM, Sibley GS, Prosnitz LR, Scher RL, Dewhirst MW. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. *Int J Radiat Oncol Biol Phys* 1997;38:285–9. [PubMed: 9226314]
8. Cuvier C, Jang A, Hill RP. Exposure to hypoxia, glucose starvation and acidosis: effect on invasive capacity of murine tumor cells and correlation with cathepsin (L + B) secretion. *Clinical and Experimental Metastasis* 1997;15:19–25. [PubMed: 9009102]

9. Sundfor K, Lyng H, Rofstad EK. Tumour hypoxia and vascular density as predictors of metastasis in squamous cell carcinoma of the uterine cervix. *British Journal of Cancer* 1998;78:822–7. [PubMed: 9743308]
10. Höckel M, Schlenger K, Höckel S, Vaupel P. Hypoxic cervical cancers with low apoptotic index are highly aggressive. *Cancer Research* 1999;59:4525–8. [PubMed: 10493500]
11. Walenta S, Wetterling M, Lehrke M, et al. High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers. *Cancer Research* 2000;60:916–21. [PubMed: 10706105]
12. Ling C, Humm J, Larson S, et al. Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality. *Int J Radiat Oncol Biol Phys* 2000;47:551–60. [PubMed: 10837935]
13. Peters KB, Brown JM. Tirapazamine: a hypoxia-activated topoisomerase II poison. *Cancer Research* 2002;62:5248–53. [PubMed: 12234992]
14. Patterson A, Ferry D, Edmunds S, et al. Mechanism of Action and Preclinical Antitumor Activity of the Novel Hypoxia-Activated DNA Cross-Linking Agent PR-104. *Clinical Cancer Research* 2007;13:3922–32. [PubMed: 17606726]
15. Tan MH, Holyoke ED, Goldrosen MC. Murine colon adenocarcinomas: syngeneic orthotopic transplantation and subsequent hepatic metastases. *Journal of the National Cancer Institute* 1977;59:1537–44. [PubMed: 909110]
16. Fidler IJ, Naito S, Pathak S. Orthotopic implantation is essential for the selection, growth, and metastasis of human renal cell cancer in nude mice. *Cancer and Metastasis Reviews* 1990;9:149–65. [PubMed: 2253314]
17. Kuo TH, Kubota T, Watanabe M, et al. Site-specific chemosensitivity of human small-cell lung carcinoma growing orthotopically compared to subcutaneously in SCID mice: the importance of orthotopic models to obtain relevant drug evaluation data. *Anticancer Research* 1993;13:627–30. [PubMed: 8391244]
18. Hoffman RM. Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic. *Investigational New Drugs* 1999;17:343–59. [PubMed: 10759402]
19. Killion JJ, Radinsky R, Fidler IJ. Orthotopic models are necessary to predict therapy of transplantable tumors in mice. *Cancer and Metastasis Reviews* 1999;17:279–84. [PubMed: 10352881]
20. Rosol TJ, Tannehill-Gregg SH, LeRoy BE, Mandl S, Contag CH. Animal models of bone metastasis. *Cancer* 2003;97:748–57. [PubMed: 12548572]
21. Bibby MC. Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages. *European Journal of Cancer* 2004;40:852–7. [PubMed: 15120041]
22. Cowen SE, Bibby MC, Double JA. Characterisation of the vasculature within a murine adenocarcinoma growing in different sites to evaluate the potential of vascular therapies. *Acta Oncologica* 1995;34:357–60. [PubMed: 7779423]
23. Greenberg NM, DeMayo F, Finegold MJ, et al. Prostate cancer in a transgenic mouse. *Proc Natl Acad Sci U S A* 1995;92:3439–43. [PubMed: 7724580]
24. Jackson EL, Willis N, Mercer K, et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. *Genes and Development* 2001;15:3243–8. [PubMed: 11751630]
25. Arvanitis C, Felsner DW. Conditional transgenic models define how MYC initiates and maintains tumorigenesis. *Seminars in Cancer Biology* 2006;16:313–7. [PubMed: 16935001]
26. Valenzuela DM, Groffen J. Four human carcinoma cell lines with novel mutations in position 12 of c-K-ras oncogene. *Nucleic Acids Res* 1986;14:843–52. [PubMed: 3945555]
27. Tran PT, Fan AC, Bendapudi P, et al. Combined Inactivation of MYC and K-Ras Oncogenes Reverses Tumorigenesis in Lung Adenocarcinomas and Lymphomas. *PLoS ONE* 2008;3:e2125. [PubMed: 18461184]
28. Reischl G, Ehrlichmann W, Bieg C, et al. Preparation of the hypoxia imaging PET tracer [18F]FAZA: reaction parameters and automation. *Applied Radiation and Isotopes* 2005;62:897–901. [PubMed: 15799867]
29. Graves EE, Quon A, Loo BW. RT_Image: An Open-Source Tool for Investigating PET in Radiation Oncology. *Technology in Cancer Research and Treatment* 2007;6:111–21. [PubMed: 17375973]

30. Raleigh JA, Chou SC, Arteel GE, Horsman MR. Comparisons among Pimonidazole Binding, Oxygen Electrode Measurements, and Radiation Response in C3H Mouse Tumors. *Radiation Research* 1999;151:580–9. [PubMed: 10319731]
31. Le Q, Chen E, Salim A, et al. An Evaluation of Tumor Oxygenation and Gene Expression in Patients with Early Stage Non-Small Cell Lung Cancers. *Clinical Cancer Research* 2006;12:1507–14. [PubMed: 16533775]
32. Nordsmark M, Bentzen SM, Rudat V, et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. *Radiotherapy and Oncology* 2005;77:18–24. [PubMed: 16098619]
33. Gross MW, Karbach U, Groebe K, Franko AJ, Mueller-Klieser W. Calibration of misonidazole labeling by simultaneous measurement of oxygen tension and labeling density in multicellular spheroids. *International Journal of Cancer* 1995;61:567–73.
34. Koch CJ, Evans SM, Lord EM. Oxygen dependence of cellular uptake of EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)acetamide] : analysis of drug adducts by fluorescent antibodies vs bound radioactivity. *British Journal of Cancer* 1995;72:869–74. [PubMed: 7547233]
35. Beck R, Roper B, Carlsen J, et al. Pretreatment 18F-FAZA PET Predicts Success of Hypoxia-Directed Radiochemotherapy Using Tirapazamine. *Journal of Nuclear Medicine* 2007;48:973–80. [PubMed: 17536108]
36. Rapisarda A, Uranchimeg B, Scudiero DA, et al. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. *Cancer Research* 2002;62:4316–24. [PubMed: 12154035]
37. Brown JM, Wilson WR. Exploiting tumor hypoxia in cancer treatment. *Nature Reviews Cancer* 2004;4:437–47.
38. Timmerman R, Paulus R, Galvin J, et al. Stereotactic Body Radiation Therapy for Inoperable Early Stage Lung Cancer. *Journal of the American Medical Association* 2010;303:1070–6. [PubMed: 20233825]
39. Chapman JD, Engelhardt EL, Stobbe CC, Schneider RF, Hanks GE. Measuring hypoxia and predicting tumor radioresistance with nuclear medicine assays. *Radiotherapy and Oncology* 1998;46:229–37. [PubMed: 9572615]
40. Piert M, Machulla HJ, Picchio M, et al. Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside. *Journal of Nuclear Medicine* 2005;46:106–13. [PubMed: 15632040]
41. Busk M, Horsman M, Jakobsen S, et al. Imaging Hypoxia in Xenografted and Murine Tumors With 18F-Fluoroazomycin Arabinoside: A Comparative Study Involving microPET, Autoradiography, Po2-Polarography, and Fluorescence Microscopy. *Int J Radiat Oncol Biol Phys* 2008;70:1202–12. [PubMed: 18313528]
42. Dehdashti F, Mintun MA, Lewis JS, et al. In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM. *European Journal of Nuclear Medicine and Molecular Imaging* 2003;30:844–50. [PubMed: 12692685]
43. Eschmann S, Paulsen F, Reimold M, et al. Prognostic Impact of Hypoxia Imaging with 18F-Misonidazole PET in Non-Small Cell Lung Cancer and Head and Neck Cancer Before Radiotherapy. *Journal of Nuclear Medicine* 2005;46:253–60. [PubMed: 15695784]
44. Li L, Yu J, Xing L, et al. Serial Hypoxia Imaging With 99mTc-HL91 SPECT to Predict Radiotherapy Response in Non-small Cell Lung Cancer. *American Journal of Clinical Oncology* 2006;29:628–33. [PubMed: 17149002]
45. Spence A, Muzi M, Swanson K, et al. Regional Hypoxia in Glioblastoma Multiforme Quantified with [18F]Fluoromisonidazole Positron Emission Tomography before Radiotherapy: Correlation with Time to Progression and Survival. *Clinical Cancer Research* 2008;14:2623–30. [PubMed: 18451225]
46. Brown JM. Tumor Microenvironment and the Response to Anticancer Therapy. *Cancer Biology & Therapy* 2002;1:453–8. [PubMed: 12496469]
47. Rischin D, Hicks RJ, Fisher R, et al. Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. *Journal of Clinical Oncology* 2006;24:2098–104. [PubMed: 16648512]

Figure 1.

In vivo imaging and *ex vivo* immunohistochemistry of murine models of lung cancer. **A.** Results obtained from bilateral subcutaneous A549 xenograft tumors (top row), orthotopically implanted A549 xenograft tumors (second row), spontaneous K-ras-induced lung tumors (third row), and spontaneous Myc-induced lung tumors (bottom row) are shown. The data collected from each subject included micro-computed tomography (microCT, left column), fluorodeoxyglucose micro-positron emission tomography (FDG microPET, second column), fluoroazomycin arabinoside microPET (FAZA microPET, third column), and pimonidazole (green) and DAPI (blue) immunohistochemistry (IHC, right column). Displayed intensity ranges for *in vivo* imaging are given at top. Relevant features are labeled on the CT images,

including tumor (T) and heart (H). **B** and **C**. Mean FDG and FAZA uptake observed in microPET studies of murine models of lung cancer. The light colored bars are quantified in units of tumor:background ratio (T:B, left vertical axis), while the dark colored bars are in units of percent injected dose per gram of tissue (% ID/g, right vertical axis). Blue: subcutaneous A549 xenograft tumors. Red: orthotopic A549 xenograft tumors. Green: spontaneous K-ras-induced lung tumors. Purple: spontaneous Myc-induced lung tumors. The measurements reported for the subcutaneous tumors indicate the mean and standard deviation over a region-of-interest defined over the tumor, while the measurements for the orthotopic and spontaneous tumors are the mean and standard deviation over a region-of-interest encompassing the lungs and excluding the heart.

Figure 2.

Response of lung tumor cell lines to PR-104 treatment *in vitro*. **A.** γ H2AX (red) and DAPI (blue) immunohistochemistry of human A549, murine Myc-induced lung carcinoma, and murine K-ras-induced lung carcinoma cells treated with 100 μ M PR-104 for four hours in 21%, 2%, or 0.5% O_2 . Untreated cells of each type are shown as a control. **B.** Quantitated average total γ H2AX signal per cell for each treatment group and cell type. Blue: untreated cells. Red: cells treated at 21% O_2 . Green: cells treated at 2% O_2 . Purple: cells treated at 0.5% O_2 . All measurements for a cell type are normalized to the average total γ H2AX signal per cell for that cell type treated at 21% O_2 .

a. **b.** **Figure 3.**

Response of murine lung tumor models to PR-104 treatment *in vivo*. **A.** γ H2AX (red) and DAPI (blue) immunohistochemistry of subcutaneous and orthotopic A549 tumor xenografts, spontaneous and subcutaneous Myc-induced lung carcinomas, and spontaneous and subcutaneous K-ras-induced lung carcinomas treated with a single intraperitoneal dose of 1.8 mmol/kg PR-104 for 18 hours prior to tissue harvesting. Data collected from subcutaneous A549 tumors treated with 10 Gy of ionizing radiation are shown as a positive control. **B.** Quantitated average total γ H2AX signal per cell for each treatment group and tumor type. Blue: untreated tumors. Red: PR-104 treated tumors. Green: IR-treated tumors. All measurements

for a tumor type are normalized to the average total γ H2AX signal per cell for that tumor observed without treatment.

Figure 4.

In vivo Eppendorf electrode measurements of oxygenation of human lung cancers. **A.** Box and whisker plot showing the distribution of median tumor pO₂ measurements for 21 non small cell lung cancer patients. **B.** Box and whisker plot showing the distribution of the percentage of oxygen measurements below 2.5 mm Hg (HF2.5) and below 10 mm Hg (HF10) for this patient sample. **C.** Pie chart demonstrating the proportion of lung cancer patients with HF2.5 above and below a threshold value of 20%. **D.** Pie chart demonstrating the proportion of lung cancer patients with HF10 above and below a threshold value of 20%.